All Oncology News

The FDA has approved darolutamide tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer.

Amrita Krishnan, MD, discusses emerging data on bispecific antibodies, the exploration of the antibody-drug conjugate belantamab mafodotin, and the challenges of delivering CAR T-cell therapy in the right setting to the appropriate patients with multiple myeloma.

The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with unresectable or metastatic HER2-low breast cancer.

What began as a small community effort seven decades ago has resulted in a new series of grants to accelerate groundbreaking research at Sylvester Comprehensive Cancer Center at the University of Miami Leonard M. Miller School of Medicine.

The FDA has approved a new tablet formulation of acalabrutinib for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and for those with relapsed or refractory mantle cell lymphoma.

Research investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.

The combination of azacitidine and quizartinib produced preliminary responses in patients with myelodysplastic syndrome and myelodysplastic syndrome/myeloproliferative neoplasms whose tumors harbored FLT3 or CBL mutations, according to data from a phase 1/2 trial (NCT04493138).

Avelumab plus talazoparib showcased a favorable toxicity profile and overall modest activity in patients with mismatch repair–proficient endometrial cancer; however, immunogenomic profiling revealed a certain subset who might derive benefit from the doublet, warranting further investigation.

Giuseppe Lo Russo, MD, PhD, highlights the future role of liquid biopsy, the evolution of targeted therapies for KRAS G12C mutations, data to look forward to with EGFR-targeted agents, and the striking effects the COVID-19 pandemic has had on the mortality rates of patients with lung cancer.

Yasir Y. Elamin, MD, explained the rationale, design, and key findings of a phase 2 study evaluating poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer.

The O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham has been awarded a five-year Cancer Center Core Support Grant of $27,477,570 from the National Cancer Institute.

The European Commission has approved olaparib as a single agent or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutated, HER2-negative, high-risk early breast cancer.

Prevention and mitigation of cardiovascular events, such as thrombohemorrhagic complications, have been the main goal of treatment development for patients with essential thrombocythemia and polycythemia vera.

National Cancer Institute-designated comprehensive cancer centers routinely perform clinical trial site self-assessments. However, participation in these types of assessments is far less commonplace among community oncology sites.

Sintilimab in combination with a bevacizumab biosimilar plus pemetrexed and cisplatin induced a progression-free survival benefit of 2.6 months compared with chemotherapy alone for patients with EGFR-mutated, locally advanced or metastatic non–small cell lung cancer, according to interim findings from the ongoing phase 3 ORIENT-31 trial.

The addition of pembrolizumab to lenvatinib did not significantly improve overall survival or progression-free survival over lenvatinib alone when used in the frontline treatment of patients with unresectable hepatocellular carcinoma, missing the dual primary end points of the phase 3 LEAP-002 trial.

Vanderbilt University Medical Center and the University of Zambia are partnering on a program to develop a cadre of researchers and educators to lead cancer epidemiology research and training in Zambia and to encourage U.S.-based researchers to engage in cancer research in low- and middle-income countries.

The novel PSMAxCD38 costimulatory bispecific antibody REGN5678 has shown encouraging efficacy in combination with cemiplimab in patients with advanced metastatic castration-resistant prostate cancer, according to preliminary findings from an ongoing phase 1/2 trial (NCT03972657).

Pembrolizumab plus docetaxel failed to elicit a statistically significant improvement in overall survival and radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer, missing the coprimary end points of the phase 3 KEYNOTE-921 trial.

Liposomal irinotecan did not provide an overall survival benefit compared with topotecan as a second-line treatment for patients with small cell lung cancer who progressed on or after first-line platinum-based chemotherapy.

HER3 has been shown to have a small amount of tyrosine kinase activity, making it an attractive target for the treatment of patients who have progressed after treatment with tyrosine kinase inhibitors. Preclinical data have shown that targeting HER3 and EGFR can overcome acquired resistance to EGFR inhibition.

The fully human BCMA-directed CAR T-cell therapy, CT103A, demonstrated deepening efficacy with an acceptable toxicity profile in patients with relapsed or refractory multiple myeloma, according to updated data from the phase 1/2 FUMANBA-1 trial.

Eftilagimod alpha plus pembrolizumab demonstrated promising benefits in overall survival and progression-free survival as a second-line treatment in patients with non–small cell lung cancer who progressed on anti–PD-1/anti–PD-L1 therapy.

Poziotinib produced an encouraging overall response rate in patients with non–small cell lung cancer harboring EGFR exon 20 mutations, meeting the primary end point in cohort 1 of a phase 2 trial.

The FDA has granted a fast track designation to OP-1250 for the treatment of patients with ER-positive, HER2- metastatic breast cancer who have progressed following at least 1 line of endocrine therapy with at least 1 line administered in combination with a CDK4/6 inhibitor.

Carrie Horton, MS, CGC, discusses how the findings from a retrospective analysis of germline testing rates among racially diverse groups of men with prostate cancer will guide future research and influence the steps community oncologists can take to increase testing rates.

The subcutaneous administration of atezolizumab produced non-inferior levels of the agent in the blood compared with intravenous atezolizumab in immunotherapy-naïve patients with locally advanced or metastatic non–small cell lung cancer who failed platinum-based chemotherapy.

The menu of tissue-agnostic oncology drug approvals is growing, generating new treatment options for patients with rare cancers and strengthening the rationale for broad next-generation sequencing.

Florida Cancer Specialists & Research Institute welcomes medical oncologist Mariuxi Viteri Malone, MD, to the statewide practice.

Ropeginterferon alfa-2b produced durable complete hematologic responses without phlebotomy and showcased a consistent safety profile in Japanese patients with polycythemia vera, according to findings from a phase 2 study (NCT04182100) presented during the 2022 EHA Congress.